Literature DB >> 2963214

New therapy for endometriosis.

R L Barbieri.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2963214     DOI： 10.1056/NEJM198802253180810

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

1.  Transdermal oestrogene application a contraindication in therapy of endometriosis with gonadotropin-releasing hormone analogues.

Authors:  A Rosen; M Klein; A Beck
Journal:  Klin Wochenschr       Date:  1990-05-17

2.  Long-term effects on bone mineral density and bone metabolism of 6 months' treatment with gonadotropin-releasing hormone analogues in Japanese women: comparison of buserelin acetate with leuprolide acetate.

Authors:  Kazuya Makita; Ken Ishitani; Hiroaki Ohta; Fumi Horiguchi; Shiro Nozawa
Journal:  J Bone Miner Metab       Date:  2005       Impact factor: 2.626

Review 3.  Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical use in sex hormone-related conditions.

Authors:  P Chrisp; K L Goa
Journal:  Drugs       Date:  1991-02       Impact factor: 9.546

Review 4.  Nafarelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical potential in sex hormone-related conditions.

Authors:  P Chrisp; K L Goa
Journal:  Drugs       Date:  1990-04       Impact factor: 9.546

5.  Knockdown hsa_circ_0063526 inhibits endometriosis progression via regulating the miR-141-5p / EMT axis and downregulating estrogen receptors.

Authors:  Zhangming Wei; Yi Hu; Xiang He; Mengmeng Zhang; Xinyue Zhang; Yali Wang; Xiaoling Fang; Liping Li
Journal:  Aging (Albany NY)       Date:  2021-12-30       Impact factor: 5.682
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.